Two sizeable transactions in oncology — spanning diagnostics and drug development — are underscoring how large healthcare ...

In the face of a new war crisis weighing heavily on both equities and economics alike, value hunters (both long- and ...

A new 2026 study reveals how chronic stress depletes NAD⁺, impairing immunity and accelerating liver cancer—while linking the ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new ...

Q: I need some new ways to reinforce my efforts to shed my excess body fat. It’s taking so long! — T.D., Memphis ...

For over 350 years, quinine and other extracts from the cinchona tree (Cinchona spp.) were the only effective medicines ...

The name might sound like a Nordic god, but it is actually the molecular machinery that allows many different species to eat ...

A surprising new study reveals that blocking a supposedly protective enzyme, Caspase-2, could actually backfire—raising the risk of chronic liver damage and cancer over time. Researchers found that ...

When a virus infects a bacterial cell, the viral genome is the first component to be fully injected into the cell, making it an ideal immune target. A bacterial enzyme anchored to the membrane ...

This important study presents a novel immunotherapy strategy for cancer. The authors develop a whole-tumor cell vaccine comprised of senescent tumor cells and a COX2 inhibitor in a hydrogel matrix.

Denali Therapeutics (NASDAQ:DNLI) founder and CEO Ryan Watts said 2026 is shaping up to be a pivotal year for the company as ...